Please assess the completion status of the following clinical trial:

Trial Title: Erlotinib, Celecoxib and Reirradiation for Recurrent Head and Neck Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18 years or older~* Histologically or cytologically confirmed diagnosis of squamous cell or poorly differentiated carcinomas of the head and neck or lymphoepithelioma~* Prior radiation to the head and neck, surgery or chemotherapy is allowed~* Karnofsky performance status of \>= 70%~* Intact organ and bone marrow function~* Obtained informed consent~Exclusion Criteria:~* Demonstration of metastatic disease (i.e. M1 disease).~* Incomplete healing from previous surgery~* Pregnancy or breast feeding (men and women of child-bearing potential are eligible but must consent to using effective contraception during therapy and for at least 3 months after completing therapy)~* Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure (CHF), unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements~* Patients with clinically significant pulmonary dysfunction, cardiomyopathy, or any history of clinically significant CHF are excluded. The exclusion of patients with active coronary artery disease will be at the discretion of the attending physician.~* Uncontrolled active infection unless curable with treatment of their cancer.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- erlotinib + celecoxib (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).